Physician profile
Joyce Jackowski
NPI 1295774784
$2,320.01
in general payments reported to CMS, 2019-2025
33 companies · $16.07 in 2025
The $16.07 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $1,574 · 2023: $131 · 2024: $30.79 · 2025: $16.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $247.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $194.41 | 2022-2024 | |
| Seagen INC. | $156.94 | 2021-2023 | Padcev |
| Celgene Corporation | $151.19 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $141.14 | 2022 | |
| Incyte Corporation | $111.95 | 2021-2022 | |
| Pfizer INC. | $109.05 | 2021-2022 | |
| Abbvie INC. | $105.94 | 2022-2025 | |
| Janssen Biotech, INC. | $98.85 | 2021-2023 | Darzalex, Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $84.61 | 2021-2022 | |
| Myovant Sciences INC. | $77.24 | 2021-2022 | |
| Gilead Sciences, INC. | $76.74 | 2022 | |
| Lilly USA, LLC | $74.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.54 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $50.37 | 2023 | Imbruvica |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.30 | 2022 | |
| Deciphera Pharmaceuticals INC. | $46.33 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.18 | 2022 | |
| Daiichi Sankyo INC. | $44.40 | 2021 | |
| Eisai INC. | $41.31 | 2022 | |
| Epizyme, INC. | $41.26 | 2022 | |
| Genzyme Corporation | $41.14 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $40.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.99 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $34.94 | 2022 | |
| Puma Biotechnology, INC. | $33.30 | 2022 | |
| G1 Therapeutics, INC. | $23.81 | 2022 | |
| Heron Therapeutics, INC. | $19.98 | 2022 | |
| Karyopharm Therapeutics INC. | $18.56 | 2022 | |
| Array Biopharma INC | $17.81 | 2021 | |
| Acrotech Biopharma INC. | $16.75 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.09 | 2021 | |
| Astellas Pharma US INC | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Jackowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.